11 comments for “Clogged arteries

  1. Distant Relative
    March 13, 2018 at 12:16

    #ditchthecarbs

    • March 13, 2018 at 15:35

      Wot, allofem?

      • Distant Relative
        March 13, 2018 at 16:37

        🙂 30-50g per day only.
        diet doctor dot com
        Lost 10 kilos eating HFLC since the autumn. 🙂

  2. Chuckles
    March 13, 2018 at 18:05

    With all the roadworks, the A14 seems to be clogged most of the time these days.

    • March 13, 2018 at 18:41

      Why won’t anyone at N.O. take things seriously? 🙂

  3. dearieme
    March 13, 2018 at 18:34

    I’ve had my nose in a book about this area. An opinion was quoted to the effect of the whole diet/cholesterol/statin business being the greatest scam in the history of medicine. The author’s own view was that it damn near amounted to a Crime Against Humanity.

    I don’t believe in Crimes Against Humanity, but I am otherwise sympathetic to his general drift.

    • Chuckles
      March 13, 2018 at 19:17

      Yup, ditto here, dearime.

  4. Distant Relative
    March 13, 2018 at 19:32

    Re Trump’s unclogging. Pompeo was a tad scathing about Assange last year. {shrugs shoulders}
    Woman in top job at Clowns in America is one in the eye for Hellary who is currently falling down steps in India. Why India??? Must be coz they revere cows over there.

  5. March 13, 2018 at 20:18

    🙂

  6. Distant Relative
    March 13, 2018 at 21:59

    2 mins worth of Pompeo on Hellary https://www.youtube.com/watch?v=RIivWISwrCw

  7. dearieme
    March 13, 2018 at 22:39

    Aha! A bloody ha! So lowering ‘LDL cholesterol’ and raising ‘HDL cholesterol’ will save us all from heart attacks and strokes, will it? Oh no it bloody won’t. Scam indeed!

    http://www.nejm.org/doi/full/10.1056/NEJMoa1609581

    RESULTS
    At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. … the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group …

    CONCLUSIONS
    Although … evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease.

Leave a Reply

Your email address will not be published. Required fields are marked *